Literature DB >> 2691209

Impact of randomized clinical trials on medical practices.

J P Boissel1.   

Abstract

The randomized clinical trial (RCT) is the most powerful tool available to assess the effectiveness of a medical procedure. It complies with the fundamentals of scientific human experimentation and it is accepted, as such, by the researchers as the yardstick of medical progress. Therefore RCTs should have had a major impact on current medical practices through health policy makers and prescribers. Though they are limited in number and they have investigated few medical fields, studies on the impact of RCTs on medical practice have shown large and frequent discrepancies between scientific data made available from RCTs and current prescription practices in France, the United States, Finland, Holland, and elsewhere. Hence the above expectation is frustrated because doctors are not trained to weigh the evidence on treatment benefit-risk ratios, to read clinical research reports, or to select the appropriate information. In addition, the number of pending problems addressed by RCTs are too few, too slow to give the answers, inadequately sized, and their outcome measures are more often than not inappropriate. Doctors are reluctant to participate in clinical trials despite such participation being one of their duties. Governmental agencies barely fund clinical trials. Researchers do not formulate the right questions.

Entities:  

Mesh:

Year:  1989        PMID: 2691209     DOI: 10.1016/0197-2456(89)90051-2

Source DB:  PubMed          Journal:  Control Clin Trials        ISSN: 0197-2456


  7 in total

1.  Oncologists' use of quality of life information: results of a survey of Eastern Cooperative Oncology Group physicians.

Authors:  A Bezjak; P Ng; R Skeel; A D Depetrillo; R Comis; K M Taylor
Journal:  Qual Life Res       Date:  2001       Impact factor: 4.147

2.  Doctors' perception of pertinent information. Results of a survey of a random sample of French general practitioners. GEP (Groupe d'Etude de la Prescription).

Authors:  G Figon; J P Boissel; J C Peyrieux
Journal:  Eur J Clin Pharmacol       Date:  1992       Impact factor: 2.953

3.  Bridging the gap between therapeutic research results and physician prescribing decisions: knowledge transfer, a prerequisite to knowledge translation.

Authors:  Jean-Pierre Boissel; Emmanuel Amsallem; Michel Cucherat; Patrice Nony; Margaret C Haugh
Journal:  Eur J Clin Pharmacol       Date:  2004-09-16       Impact factor: 2.953

4.  The research-practice gap and the role of decision analysis in closing it.

Authors:  J Dowie
Journal:  Health Care Anal       Date:  1996-02

5.  Use of Bevacizumab and Ranibizumab for Wet Age-Related Macular Degeneration: Influence of CATT Results and Introduction of Aflibercept.

Authors:  Suzann Pershing; Nidhi Talwar; Stephen T Armenti; Joseph Grubbs; Julie M Rosenthal; Vaidehi S Dedania; Joshua D Stein
Journal:  Am J Ophthalmol       Date:  2019-05-15       Impact factor: 5.258

6.  Physicians' preferences for active-controlled versus placebo-controlled trials of new antihypertensive drugs.

Authors:  Scott D Halpern; Peter A Ubel; Jesse A Berlin; Raymond R Townsend; David A Asch
Journal:  J Gen Intern Med       Date:  2002-09       Impact factor: 5.128

7.  Altmetrics Attention Scores for Randomized Controlled Trials in Total Joint Arthroplasty Are Reflective of High Scientific Quality: An Altmetrics-Based Methodological Quality and Bias Analysis.

Authors:  Kyle N Kunze; Michelle Richardson; David N Bernstein; Ajay Premkumar; Nicolas S Piuzzi; Alexander S McLawhorn
Journal:  J Am Acad Orthop Surg Glob Res Rev       Date:  2020-12
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.